Brentuximab Vedotin and Nivolumab for Relapsed or Refractory Classic Hodgkin Lymphoma: Long-Term Follow-up Results from the Single-Arm Phase 1/2 Study

被引：23

作者：

Moskowitz, Alison J. ^{[1
]}

Advani, Ranjana H. ^{[2
]}

Bartlett, Nancy L. ^{[3
]}

Vose, Julie M. ^{[4
]}

Ramchandren, Radhakrishnan ^{[5
]}

Feldman, Tatyana A. ^{[6
]}

LaCasce, Ann S. ^{[7
]}

Christian, Beth A. ^{[8
]}

Ansell, Stephen M. ^{[9
]}

Moskowitz, Craig H. ^{[10
]}

Brown, Lisa ^{[11
]}

Taft, David ^{[11
]}

Ansari, Sahar ^{[11
]}

Zak, Daniel E. ^{[11
]}

Sacchi, Mariana ^{[12
]}

Manley, Thomas ^{[11
]}

Herrera, Alex F. ^{[13
]}

机构：

[1] Mem Sloan Kettering Canc Ctr, Dept Med, Lymphoma Serv, 1275 York Ave, New York, NY 10021 USA

[2] Stanford Univ, Med Ctr, Palo Alto, CA 94304 USA

[3] Washington Univ, Sch Med, St Louis, MO USA

[4] Univ Nebraska Med Ctr, Div Hematol Oncol, Omaha, NE USA

[5] Karmanos Canc Inst, Detroit, MI USA

[6] Hackensack Univ, Med Ctr, Hackensack, NJ USA

[7] Dana Farber Canc Inst, Boston, MA 02115 USA

[8] James Canc Hosp, Columbus, OH USA

[9] Mayo Clin, Rochester, MN USA

[10] Univ Miami, Sylvester Comprehens Canc Ctr, Miami, FL USA

[11] Seattle Genet Inc, Bothell, WA USA

[12] Bristol Myers Squibb, Princeton, NJ USA

[13] City Hope Natl Med Ctr, 1500 E Duarte Rd, Duarte, CA 91010 USA

来源：

BLOOD | 2019年 / 134卷

关键词：

D O I：

10.1182/blood-2019-122576

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

238

引用

页数：8

共 50 条

[11] Phase II single-arm study of brentuximab vedotin in Chinese patients with relapsed/refractory classical Hodgkin lymphoma or systemic anaplastic large cell lymphoma
Song, Yuqin
Guo, Ye
Huang, Huiqiang
Li, Wei
Ke, Xiaoyan
Feng, Jifeng
Xu, Wei
Miao, Harry
Kinley, Judith
Song, Gregory
Dai, Yi
Wang, Hui
Zhu, Jun
EXPERT REVIEW OF HEMATOLOGY, 2021, 14 (09) : 867 - 875
[12] Nivolumab for Relapsed/Refractory Classic Hodgkin Lymphoma After Failure of Autologous Hematopoietic Cell Transplantation: Extended Follow-Up of the Multicohort Single-Arm Phase II CheckMate 205 Trial
Armand, Philippe
Engert, Andreas
Younes, Anas
Fanale, Michelle
Santoro, Armando
Zinzani, Pier Luigi
Timmerman, John M.
Collins, Graham P.
Ramchandren, Radhakrishnan
Cohen, Jonathon B.
De Boer, Jan Paul
Kuruvilla, John
Savage, Kerry J.
Trneny, Marek
Shipp, Margaret A.
Kato, Kazunobu
Sumbul, Anne
Farsaci, Benedetto
Ansell, Stephen M.
JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (14) : 1428 - +
[13] SINGLE-ARM STUDY OF BRENTUXIMAB VEDOTIN IN PATIENTS WITH RELAPSED OR REFRACTORY HODGKIN LYMPHOMA WHO ARE INELIGIBLE FOR STEM CELL TRANSPLANTATION OR MULTIAGENT CHEMOTHERAPY
Walewski, J.
Hellmann, A.
Siritanaratkul, N.
Ozsan, G. H.
Ozcan, M.
Chuncharunee, S.
Goh, A. S.
Jurczak, W.
Koren, J.
Wang, B.
Singh, S.
Huebner, D.
Engert, A.
HAEMATOLOGICA, 2016, 101 : 56 - 56
[14] Durable remissions in a pivotal phase 2 study of brentuximab vedotin in relapsed or refractory Hodgkin lymphoma
Gopal, Ajay K.
Chen, Robert
Smith, Scott E.
Ansell, Stephen M.
Rosenblatt, Joseph D.
Savage, Kerry J.
Connors, Joseph M.
Engert, Andreas
Larsen, Emily K.
Chi, Xuedong
Sievers, Eric L.
Younes, Anas
BLOOD, 2015, 125 (08) : 1236 - 1243
[15] Results of a Pivotal Phase II Study of Brentuximab Vedotin for Patients With Relapsed or Refractory Hodgkin's Lymphoma
Younes, Anas
Gopal, Ajay K.
Smith, Scott E.
Ansell, Stephen M.
Rosenblatt, Joseph D.
Savage, Kerry J.
Ramchandren, Radhakrishnan
Bartlett, Nancy L.
Cheson, Bruce D.
de Vos, Sven
Forero-Torres, Andres
Moskowitz, Craig H.
Connors, Joseph M.
Engert, Andreas
Larsen, Emily K.
Kennedy, Dana A.
Sievers, Eric L.
Chen, Robert
JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (18) : 2183 - 2189
[16] PENPULIMAB FOR RELAPSED/REFRACTORY (R/R) CLASSICAL HODGKIN'S LYMPHOMA (CHL): EXTENDED FOLLOW-UP OF THE MULTICENTER, SINGLE-ARM, PHASE 2 STUDY
Song, Yuqin
Zhou, Keshu
Jin, Chuan
Qian, Zhengzi
Hou, Ming
Fan, Lei
Li, Fei
Ding, Kaiyang
Zhou, Hui
Li, Xiaoling
Chen, Bing
Sun, Xiuhua
Song, Xianmin
Jiang, Ming
Zhang, Qingyuan
Liu, Lihong
Yu, Guohua
Hu, Yu
Zhao, Zheng
Liu, Ligen
Xue, Hongwei
Luo, Jun
He, Bai
Yao, Zhifang
Xu, Fenghua
Zhao, Min
Li, Baiyong
Xia, Yu
Zhu, Jun
JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2022, 10 : A598 - A598
[17] Brentuximab Vedotin, Nivolumab, Doxorubicin, and Dacarbazine for Advanced Stage Classical Hodgkin Lymphoma: Efficacy and Safety Results from the Single Arm Phase 2 Study
Lee, Hun Ju
Flinn, Ian W.
Melear, Jason
Ramchandren, Rod
Friedman, Judah
Burke, John M.
Linhares, Yuliya
Gonzales, Paul Alan
Raval, Mihir
Chintapatla, Rangaswamy
Feldman, Tatyana
Yimer, Habte A.
Islas-Ohlmayer, Miguel
Dean, Asad
Rana, Vishal
Gandhi, Mitul
Renshaw, John Scott
Ho, Linda
Fanale, Michelle A.
Guo, Wenchuan
Yasenchak, Chris
BLOOD, 2023, 142
[18] Long-term results of brentuximab vedotin in relapsed and refractory Hodgkin lymphoma: multi-center real-life experience
Ozbalak, Murat
Salihoglu, Ayse
Soysal, Teoman
Karadogan, Ihsan
Paydas, Semra
Ozdemir, Evren
Yildiz, Birol
Karadurmus, Nuri
Kaynar, Leylagul
Yagci, Munci
Ozkocaman, Vildan
Topcuoglu, Pervin
Ozcan, Muhit
Birtas, Elif
Goker, Hakan
Ferhanoglu, Burhan
ANNALS OF HEMATOLOGY, 2020, 99 (02) : 301 - 307
[19] Long-term results of brentuximab vedotin in relapsed and refractory Hodgkin lymphoma: multi-center real-life experience
Murat Özbalak
Ayşe Salihoğlu
Teoman Soysal
İhsan Karadoğan
Semra Paydaş
Evren Özdemir
Birol Yıldız
Nuri Karadurmuş
Leylagül Kaynar
Münci Yagci
Vildan Özkocaman
Pervin Topçuoğlu
Muhit Özcan
Elif Birtaş
Hakan Göker
Burhan Ferhanoglu
Annals of Hematology, 2020, 99 : 301 - 307
[20] Long-Term Results of Brentuximab Vedotin in Relapsed and Refractory Hodgkin Lymphoma: Multi-Center Real-Life Experience
Ferhanoglu, A. Burhan
Ozbalak, Murat
Salihoglu, Ayse
Soysal, Teoman
Karadogan, Ihsan
Paydas, Semra
Ozdemir, Evren
Yildiz, Birol
Karadurmus, Nuri
Kaynar, Leylagul
Yegin, Zeynep Arzu
Ozbalak, Ezgi Pinar
Sucak, Gulsan
Ozkocaman, Vildan
Topcuoglu, Pervin
Ozcan, Muhit
Birtas, Elif
Goker, Hakan
BLOOD, 2017, 130

← 1 2 3 4 5 →